Finally, we provide evidence that this hybrid TCA cycle can be targeted for therapeutic purposes using available inhibitors, including an FDA‐approved molecule, and identify IDH1 as a PCa metabolic vulnerability. The gene discussed is IDH1; the disease is posterior cortical atrophy.